Theravance Biopharma Inc (TBPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theravance Biopharma Inc (TBPH) has a cash flow conversion efficiency ratio of -0.020x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($296.72 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Theravance Biopharma Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Theravance Biopharma Inc total liabilities for a breakdown of total debt and financial obligations.
Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SHENWAN HONGYUAN GR.H YC1
F:2X2A
|
-0.013x |
|
Scandinavian Tobacco Group A/S
CO:STG
|
0.027x |
|
Shanghai Kelai Mechatronics
SHG:603960
|
0.027x |
|
Teekay Corporation
NYSE:TK
|
0.037x |
|
M Grass Ecology and Environment Group Co Ltd
SHE:300355
|
0.115x |
|
Yatharth Hospital & Trauma Care Services Limited
NSE:YATHARTH
|
0.006x |
|
Shinkong Synthetic Fiber Corp
TW:1409
|
-0.061x |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
0.022x |
Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see TBPH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $296.72 Million | $238.54 Million | 0.804x | +1323.44% |
| 2024-12-31 | $175.54 Million | $-11.54 Million | -0.066x | +48.16% |
| 2023-12-31 | $213.00 Million | $-27.00 Million | -0.127x | +70.05% |
| 2022-12-31 | $441.80 Million | $-186.99 Million | -0.423x | -168.94% |
| 2021-12-31 | $-338.57 Million | $-207.86 Million | 0.614x | -25.53% |
| 2020-12-31 | $-303.75 Million | $-250.40 Million | 0.824x | -22.53% |
| 2019-12-31 | $-223.84 Million | $-238.20 Million | 1.064x | -51.36% |
| 2018-12-31 | $-51.59 Million | $-112.87 Million | 2.188x | +225.33% |
| 2017-12-31 | $115.18 Million | $-201.05 Million | -1.746x | -517.60% |
| 2016-12-31 | $350.23 Million | $-98.99 Million | -0.283x | +59.31% |
| 2015-12-31 | $243.06 Million | $-168.86 Million | -0.695x | -14.94% |
| 2014-12-31 | $289.79 Million | $-175.16 Million | -0.604x | -108.51% |
| 2013-12-31 | $-17.04 Million | $-120.96 Million | 7.101x | -89.81% |
| 2012-12-31 | $-1.71 Million | $-119.11 Million | 69.653x | +11648.91% |
| 2011-12-31 | $-140.72 Million | $-83.43 Million | 0.593x | -- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic n… Read more